Patents Assigned to MedImmune, LLC
  • Patent number: 12018068
    Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: June 25, 2024
    Assignees: MedImmune, LLC, Humabs BioMed SA
    Inventors: Qun Wang, Charles K. Stover, Meghan Pennini, Chew-shun Chang, Xiaodong Xiao, Jamese Hilliard, Gilad Kaplan, Davide Corti, Elisabetta Cameroni, Martina Beltramello
  • Patent number: 11970527
    Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: April 30, 2024
    Assignees: MedImmune, LLC, Humabs BioMed SA
    Inventors: Christine Tkaczyk, Bret Sellman, Martin Borrok, III, Davide Corti, Andrea Minola
  • Patent number: 11971377
    Abstract: The present invention describes a versatile, robust and environmentally controlled platform with a linear temperature gradient for massively parallel chemical or biochemical processing. This apparatus is capable of probing the phase transition behavior of macromolecules in solution, both thermodynamically and kinetically. This includes—but is not limited to—liquid/liquid phase transition behavior of antibody solutions and in situ gelation of thermo-responsive polymers. The device can be operated in a multiplex fashion using a controlled temperature gradient architecture and visualized by dark field microscopy or by other optical intensity measurements.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: April 30, 2024
    Assignees: The Penn State Research Foundation, MEDIMMUNE LLC
    Inventors: Tinglu Yang, Bradley Rogers, Jifeng Zhang, Paul S. Cremer
  • Patent number: 11939382
    Abstract: The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 26, 2024
    Assignee: MedImmune, LLC
    Inventors: Yariv Mazor, Yue Wang, Gordon Moody, Deepali Malhotra, Michael Overstreet, Eleanor Clancy-Thompson, Karin Lee, Stacy Pryts, Scott Hammond
  • Patent number: 11932682
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: March 19, 2024
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • Patent number: 11926657
    Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: March 12, 2024
    Assignee: MEDIMMUNE, LLC
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Godfrey Jonah Rainey, Cuihua Gao, Srinath Kasturirangan, Changshou Gao
  • Patent number: 11912782
    Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: February 27, 2024
    Assignee: MedImmune, LLC
    Inventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
  • Patent number: 11845791
    Abstract: The present disclosure is directed to human GDF-15-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect human GDF-15 and/or in methods of treating cancer or body weight loss, including cachexia, associated with over-expression of human GDF-15.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: December 19, 2023
    Assignee: MEDIMMUNE, LLC
    Inventors: Claire Dobson, Fiona Cusdin, Darren Schofield, Peter Cariuk, Elaine Hurt, Margareta Ek, Carina Johansson, Jenny Sandmark
  • Patent number: 11798653
    Abstract: Methods for determining treatments for cancer patients are disclosed.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: October 24, 2023
    Assignee: MEDIMMUNE, LLC
    Inventors: Li Yu, Harry Yang, Mohammed Dar, Lorin Roskos, Jean-Charles Soria, Charles Ferte, Wei Zhao, Aline Gendrin Brokmann, Jolyon Faria, Pralay Mukhopadhyay, Ikbel Achour
  • Patent number: 11787853
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: October 17, 2023
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary Mcauliffe, Davide Corti, Antonio Lanzavecchia
  • Patent number: 11767369
    Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: September 26, 2023
    Assignee: MedImmune, LLC
    Inventors: Ping Tsui, Martin Borrok, William Dall'Acqua, Yanli Wu, Nurten Beyaz-Kavuncu
  • Patent number: 11759526
    Abstract: The present invention provides a bioconjugation method and compounds for use therein. The bioconjugation method comprises the step of conjugating a biological molecule containing a first unsaturated functional group with a payload comprising a second unsaturated functional group, wherein the first and second unsaturated functional groups are complementary to each other such that conjugation is a reaction of said functional groups via a Diels-Alder reaction which forms a cyclohexene ring.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: September 19, 2023
    Assignees: MedImmune, LLC, The Regents Of The University Of California
    Inventors: Ronald James Christie, Changshou Gao, Andre Henri St. Amant, Javier Read de Alaniz
  • Patent number: 11608375
    Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: March 21, 2023
    Assignee: MedImmune, LLC
    Inventors: Nabendu Pore, Martin J. Borrok, III, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Partha Chowdhury
  • Patent number: 11578119
    Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: February 14, 2023
    Assignees: MedImmune LLC, Humabs BioMed SA
    Inventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
  • Patent number: 11555175
    Abstract: This application provides improved cell culture media and cell culture methods comprising N-acetylcysteine. These improved cell culture media and cell culture methods increase cell viability, cellular growth rate and/or reduce cell doubling time of cholesterol auxotrophic cells, myeloma cells, and hybridoma cells.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: January 17, 2023
    Assignee: MedImmune, LLC
    Inventors: Brena Williams, Jeong Lee
  • Patent number: 11547756
    Abstract: Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: January 10, 2023
    Assignee: MEDIMMUNE, LLC
    Inventors: Nicole Kallewaard-Lelay, Raburn Mallory, Gabriel Robbie, Song Ren
  • Publication number: 20220411509
    Abstract: The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.
    Type: Application
    Filed: April 29, 2022
    Publication date: December 29, 2022
    Applicant: MedImmune, LLC
    Inventors: Yariv MAZOR, Yue WANG, Gordon MOODY, Deepali MALHOTRA, Michael OVERSTREET, Eleanor CLANCY-THOMPSON, Karin LEE, Stacy PRYTS, Scott HAMMOND
  • Patent number: 11482315
    Abstract: A methodology to track patient usage of an autoinjector (AI) device, and to an external or electronic adaptor (eAdaptor) adapted to be used with the AI are disclosed. The eAdaptor contains sensors (including but not limited to a temperature sensor, a sound sensor, a vibration sensor and a magnetic sensor system), a display, a microprocessor, a real time clock, and communication systems that enables the eAdaptor to capture and confirm autoinjector (AI) use, as well as injection information, and transmit such information wirelessly to a smart phone or any other data receiving system or device. Also disclosed are an internal logic to operate the eAdaptor and a smart device APP that pairs with the internal logic to guide the patients with graphical user interface (GUI) displays on the smart device.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: October 25, 2022
    Assignee: MEDIMMUNE, LLC
    Inventors: Michael C. Song, Janardhanan Anand Subramony
  • Patent number: 11446377
    Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: September 20, 2022
    Assignee: MEDIMMUNE, LLC
    Inventors: Rajesh Narwal, Paul Robbins, Joyson Karakunnel, Mohammed Dar
  • Patent number: RE49908
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: April 9, 2024
    Assignee: MedImmune, LLC
    Inventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst